TLDR;
This webinar by the Gulf Association of Endocrinology & Diabetes (GATE) focuses on the management of dyslipidemia, particularly in the context of type 2 diabetes and special populations. The speakers address the increased cardiovascular risk associated with diabetes, the importance of early and intensive LDL reduction, and the nuances of treatment in specific patient groups such as pregnant women, individuals with chronic kidney disease, and the elderly. The discussion includes guideline recommendations, the use of statins and other lipid-lowering agents, and the role of risk assessment tools.
- Cardiovascular disease is a leading cause of mortality in patients with type 2 diabetes, necessitating early and intensive LDL reduction.
- Treatment strategies for dyslipidemia should be tailored to individual patient risk profiles and specific conditions such as pregnancy or chronic kidney disease.
- New guidelines emphasize achieving specific LDL targets and utilizing biomarkers for personalized cardiovascular risk management.
Introduction and Welcome [0:06]
Dr. Tama, a consultant endocrinologist from Kuwait and the secretary of the Gulf Association of Clinical Endocrinology and Diabetes, welcomes participants to the webinar. The symposium aims to provide scientific information on the management of dyslipidemia. Dr. Tama encourages attendees to join GATE to access resources that enhance medical knowledge and stay updated on medical conditions. The association offers various activities, including an annual congress and board review.
Symposium Overview and Acknowledgements [1:13]
Dr. Tama highlights GATE's social media presence for sharing news and information. She thanks Viatris, the sponsor of the symposium, which is a CME-accredited activity. Participants who registered and attended will receive CME credits via email. The session will feature presentations from esteemed physicians, and attendees are encouraged to submit questions for the Q&A session at the end.
Management of Dyslipidemia in Type 2 Diabetes [3:11]
Dr. Darwish presents on the management of dyslipidemia in type 2 diabetes, emphasizing the increased risk of cardiovascular disease in diabetic patients. He notes that type 2 diabetes often clusters with comorbidities like hypertension and hyperlipidemia, with hyperlipidemia affecting approximately 80% of diabetic individuals. Studies in the Middle East show a high prevalence of hyperlipidemia among those with diabetes. Lowering LDL cholesterol is crucial for decreasing cardiovascular risk, with a reduction of 39 mg/dL potentially decreasing cardiovascular disease risk by 20-25%.
LDL Cholesterol Guidelines and Treatment Strategies [13:18]
Dr. Darwish explains that LDL cholesterol goals are frequently unmet in high-risk patients, citing studies from various regions. He categorizes patients into low, moderate, high, and very high-risk categories based on factors like target organ damage, diabetes duration, and other risk factors. For very high-risk patients, the recommendation is an LDL reduction greater than 50% from baseline, aiming for a goal of 1.4 mmol/L (55 mg/dL). Statins are recommended for patients with type 1 diabetes at high or very high risk, and intensification of statin therapy should be considered before combination therapy.
New Guidelines and Recommendations [22:39]
Dr. Darwish discusses new recommendations from the 2023 European Society of Cardiology guidelines, including treatment for hypertriglyceridemia and heterozygous familial hypercholesterolemia. He notes that statin treatment is recommended for primary prevention in older adults up to age 75, and may be considered for those older than 75 if at high risk. The cardiovascular risk categorization in type 2 diabetes is based on factors like atherosclerotic cardiovascular disease and diabetes scores. The presentation concludes by emphasizing that cardiovascular disease is a leading cause of mortality in type 2 diabetes, advocating for early intervention and intensive LDL reduction, and aiming for very low LDL levels in high-risk patients.
10th Gulf Endocrine Review Course and Introduction to Next Presentation [27:55]
Dr. Samir promotes the upcoming 10th Gulf Endocrine Review Course, an online event from November 5-7, offering updated information on endocrinology. He then introduces Dr. Muhammad Bashir, who will discuss the management of dyslipidemia in special populations.
Management of Dyslipidemia in Special Populations: Case 1 - Pregnancy [29:11]
Dr. Bashir presents a case of a 38-year-old woman with a history of familial dyslipidemia planning for pregnancy, whose family physician advised her to stop statins. He reviews metabolic changes during pregnancy, noting that lipid levels, including total cholesterol, triglycerides, LDL, and HDL, typically increase significantly. Lipids are essential for placental development and function. Dr. Bashir discusses the risks of cardiovascular disease in women with familial hypercholesterolemia during childbearing age and the potential delay in starting statins due to pregnancy concerns.
Statins and Pregnancy: Evidence and Recommendations [36:16]
Dr. Bashir addresses the concerns about statins and congenital malformations, noting that multiple systematic reviews have found no increased risk. However, there may be a higher risk of miscarriage, though it's unclear if this is due to the medication or other factors. The FDA removed the black box warning on cholesterol use in pregnancy in 2021, but this doesn't license the use of statins in all pregnancies. Dr. Bashir advises switching the patient to rosuvastatin, a hydrophilic statin, and continuing treatment throughout pregnancy at the maximum tolerable dose.
Management of Dyslipidemia in Special Populations: Case 2 - Chronic Kidney Disease [39:27]
Dr. Bashir presents a case of a 46-year-old man with chronic kidney disease (CKD) and an eGFR of 40 mL/min. He discusses the increased cardiovascular risk associated with CKD, noting that the same heat map representing end-stage renal disease also represents increased cardiovascular mortality. Studies on statins in patients undergoing dialysis have shown LDL reduction but no significant cardiovascular benefit. The SHARP study showed some benefit with simvastatin and ezetimibe, but only in patients not on dialysis.
Guidelines and Recommendations for CKD [46:42]
Dr. Bashir reviews guidelines from KDIGO, the European Society of Cardiology, and NICE regarding statin use in CKD patients. NICE recommends atorvastatin 20 mg for primary or secondary prevention as long as the eGFR is above 30 mL/min, aiming for a 40% reduction in primary prevention and LDL less than 2 for secondary prevention. Atorvastatin is preferred due to its lack of need for dose adjustment.
Management of Dyslipidemia in Special Populations: Case 3 - Elderly Patients [48:53]
Dr. Bashir presents a case of a 75-year-old man with hypertension and an LDL of 3.3 mmol/L. He questions whether people above 75 benefit from LDL reduction, noting that guidelines often stop at this age. Studies suggest that statins do work, but the benefits may be delayed, with a modest effect on mortality in primary prevention and a need for 2.5 years of treatment before seeing benefits. The UTOPIA 75 study in Japan showed significant benefits with ezetimibe in primary prevention.
Treatment Options and Guidelines for Elderly Patients [55:01]
Dr. Bashir advises discussing treatment options with the patient, considering the delayed benefits and potential side effects of statins. Guidelines are split, with some looking at 65 and others at 75. The American Heart Association recommends risk assessment using coronary artery calcification scores and suggests moderate-intensity statins. After discussion, the patient starts atorvastatin 10 mg, which lowers his LDL to 2.7 mmol/L. Dr. Bashir suggests adding ezetimibe, as it may provide more benefit with less exposure to adverse events.
GATE Congress Announcement and Introduction to Next Presentation [58:58]
Dr. Samir announces the upcoming GATE congress in Dubai from October 16-17 and encourages registration. He then introduces Dr. Ibrahim Mamoun, who will present on evidence-based cardiovascular risk management.
Lipids at the Core: Evidence-Based Cardiovascular Risk Management [1:00:15]
Dr. Mamoun discusses the epidemiological scale of cardiovascular mortality worldwide and the amplified cardiovascular risk in patients with diabetes. He emphasizes the need to intervene early, noting that many patients with diabetes still have LDL above target despite being on treatment. Cardiovascular disease is a global crisis, with a significant portion of deaths occurring in low and middle-income countries. Multiple risk factors dramatically amplify cardiovascular risk, with modifiable risk factors accounting for a large percentage of attributable cardiovascular risk.
The Vascular Storm and the Importance of Early Intervention [1:03:52]
Dr. Mamoun describes patients with diabetes as experiencing a "vascular storm" due to the clustering of cardiovascular risk factors. He notes that while patients and physicians often focus on glycemic targets, LDL often remains above target. Early intervention is key, as atherosclerotic injury accumulates silently over time. Statins should be used as a preventive measure, not just a reactive treatment.
LDL and Cardiovascular Risk: Evidence and Guidelines [1:12:10]
Dr. Mamoun presents evidence for the causal relationship between LDL and cardiovascular disease, noting that the longer the exposure to elevated LDL, the greater the arterial damage. He highlights that most guidelines recommend statin therapy for patients with diabetes, regardless of baseline LDL levels. The ADA and European Society of Cardiology recommend moderate to high-intensity statin therapy for patients with diabetes, with high-intensity statins recommended for those with established cardiovascular disease or higher risk.
Atorvastatin: Evidence and Safety [1:16:21]
Dr. Mamoun discusses the evidence for atorvastatin, noting that it demonstrates the shortest time to measurable clinical benefit among cholesterol-lowering agents. The ASCOT trial showed that atorvastatin reduced cardiovascular events in high-risk patients. Atorvastatin is well-tolerated in patients with diabetes, with a safety profile comparable to placebo. It requires no dose adjustment in patients with renal disease and has a consistent safety profile across different doses and age groups.
2026 Lipid Guidelines and New Concepts [1:19:50]
Dr. Mamoun reviews the 2026 American College of Cardiology/American Heart Association lipid guidelines, noting the reintroduction of LDL goals and the shift to individualized treatment goals. The guidelines emphasize earlier and more intensive LDL reduction, with specific LDL targets based on risk category. New concepts include earlier screening, the use of lipoprotein(a) as a screening tool, and the use of coronary artery calcium scoring for risk reclassification.
Summary and Conclusion [1:23:11]
Dr. Mamoun concludes by reiterating that atorvastatin is well-tolerated in patients with diabetes and that the 2026 guidelines set ambitious LDL targets. Earlier and more intensive therapy is the standard of care, with personalized tools and combination therapy reflecting a paradigm shift towards lifetime cardiovascular risk reduction.
Q&A Session: Combination Therapy and LDL Cholesterol [1:24:30]
The Q&A session begins with a discussion on combination therapy to lower LDL cholesterol. Dr. Darwish explains that his approach depends on the patient's risk profile and LDL level, often starting with a high-dose statin or combining ezetimibe with a high-dose statin. He emphasizes addressing other factors like exercise, smoking, and weight. He also notes that there are two schools of thought: sequential and combination therapy, with pharmaccogenetics potentially playing a role.
Q&A Session: Responders and Non-Responders to Statins [1:28:39]
Dr. Muhammad Bashir addresses whether there are good and poor responders to statins, noting that compliance is a major issue. He distinguishes between secondary prevention, where statins at higher doses seem to have benefits beyond LDL reduction, and primary prevention, where smaller doses and earlier introduction of ezetimibe may be preferred.
Q&A Session: Differences Between Statins and Side Effects [1:31:11]
Dr. Ibrahim Mamoun discusses the differences between statins, noting that some are more potent than others and have different mechanisms of action and side effect profiles. He emphasizes the importance of patient education and considering compliance. Dr. Darwish addresses how to tackle myalgia, suggesting stopping the medicine for a week and then restarting at interrupted doses. He also discusses elevated liver enzymes, noting that monitoring is key and other causes like fatty liver should be ruled out.
Q&A Session: LDL Lowering During Pregnancy and Statins in CKD [1:35:38]
Dr. Muhammad Bashir explains that lowering LDL during pregnancy is generally not required and may even be detrimental to placental health. He notes that the FDA's removal of the warning about statins in pregnancy doesn't mean they should be used routinely. Dr. Ibrahim Mamoun and Dr. Muhammad Bashir discuss statins in CKD, noting that while KDIGO recommends statins, they don't specifically recommend them for albuminuria.
Q&A Session: Plaque Stabilization and Risk Calculators [1:42:41]
Dr. Muhammad Bashir notes that atorvastatin at a higher dose seems to play a role in plaque stabilization. Dr. Muhammad Bashir discusses the challenges of using risk calculators, especially in this part of the world where they may not be well-suited to the population. He notes that the new PREVENT calculator and the Steno risk score for type 1 diabetes are improvements, but they need to be used with caution. Dr. Ibrahim Mamoun adds that calcium scores can be helpful in the intermediate risk category.
Q&A Session: Elevated Transaminases and Fibrates [1:46:19]
Dr. Darwish discusses how to approach elevated transaminases before starting statin therapy, emphasizing monitoring and considering risk versus benefit. Dr. Muhammad Bashir explains that combination therapy with fibrates is not routinely used unless there is a primary issue with triglycerides that needs to be tackled.
Q&A Session: Albuminuria and Plaque Stabilization [1:49:38]
The panel discusses whether statins have an effect on reducing albuminuria, noting that there is no well-established evidence to suggest that they do. Dr. Muhammad Bashir notes that atorvastatin at a higher dose seems to play a role in plaque stabilization.
Closing Remarks and Announcements [1:52:52]
Dr. Samir thanks the presenters and the audience for their participation. He announces the next GATE symposium on special topics in endocrinology: pituitary disorders, and encourages attendees to provide feedback. The session is adjourned.
